| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 918.000 +0.76% on 03/22/22 | | 925.000 unch on 04/04/22 | +6.000 (+0.65%) since 03/04/22 |
| 3-Month | 881.000 +4.99% on 01/17/22 | | 934.000 -0.96% on 01/10/22 | +9.000 (+0.98%) since 01/04/22 |
| 52-Week | 541.500 +70.82% on 12/01/21 | | 948.049 -2.43% on 12/13/21 | +127.000 (+15.91%) since 04/01/21 |
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that lenzilumab is now...
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today it...
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Services (CS) business has expanded its exclusive ’on-demand’ supply service...
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company acknowledges the presentation of results from the Phase I trial “Durable complete responses...
| 3rd Resistance Point | 925.000 |
| 2nd Resistance Point | 925.000 |
| 1st Resistance Point | 925.000 |
| Last Price | 925.000 |
| 1st Support Level | 925.000 |
| 2nd Support Level | 925.000 |
| 3rd Support Level | 925.000 |
| 52-Week High | 948.049 |
| Last Price | 925.000 |
| Fibonacci 61.8% | 792.747 |
| Fibonacci 50% | 744.775 |
| Fibonacci 38.2% | 696.802 |
| 52-Week Low | 541.500 |